Latest:
Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion+ NSCLC
Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Antonia Sepulveda, MD, PhD
Latest:
Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape
Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Richard Burkhart, MD
Latest:
Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Ongoing Research
In this seventh episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, discuss ongoing research such as the PASS-01 trial (NCT04469556) in pancreatic cancer and ways to translate advances in the metastatic setting to the curative setting.
Terufumi Kato, MD
Latest:
Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC
Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.
Lance C. Pagliaro, MD
Latest:
Dr Pagliaro on the Use of First-Line Avelumab Maintenance Therapy in Urothelial Carcinoma
Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.